Virus Peptides TRIZ Cases

Incorporating insulin receptor binding peptides into AAV capsids enhances transduction efficiency, reducing vector doses and immune responses.

Substituting surface lysine and tyrosine residues in the AAV VP3 region prevents ubiquitination, blocking proteasome degradation of the viral vector.

Cellulose serves as an affinity matrix to isolate recombinant proteins, replacing expensive urea buffers with mild elution systems to reduce costs.

Inactivating MAAP translation in AAV producer cells increases viral yield and capsid integrity during extended culture periods.

Segmenting the viral vector into RNA components and adding a stuffer fragment increases insert size capacity while preventing infectious particle assembly.

Deleting ICP0 and ICP34.5 genes in a recombinant herpes simplex virus enables high-level tumor replication while eliminating neurotoxicity in normal cells.

An anti-CRISPR construct with a germline promoter inhibits Cas9 cleavage, countering resistant allele formation and unintended ecological spread.

Modifying the adenovirus fiber AB-loop enables binding to alternative receptors, overcoming low CAR expression in cancer cells.

Directed evolution creates variant AAV capsids that overcome insufficient transduction of deeper retinal cells by wild-type vectors.

Integrase-mediated integration of mutant capsid genes into pseudo attP sites generates diverse libraries that evade neutralizing antibodies.

Segmenting detection into antibody-based serology resolves the limitation of qPCR by capturing latent infection data missed by active replication tests.

Segment viral proteins into overlapping peptides to detect immune responses, overcoming low viral load and PCR contamination issues.

SapI and SmaI endonucleases drive directional ligation to amplify polyepitopic proteins while maintaining open reading frame continuity.

Virus-like particles deliver CRISPR ribonucleoproteins to excise integrated proviral DNA from HIV reservoirs.

Mutating the DNA-binding protein inhibits adenoviral replication by 70%, resolving safety risks in vaccine development.

Nucleic acid constructs encode secretion-inducing proteins that self-assemble into compartments to package and export cellular contents from living cells.

Triplet-emitting fluor mediates energy transfer in bismuth-loaded polymers, resolving light yield loss during gamma ray detection.

Fusing HTLV p24 domains with chaperones boosts detection sensitivity, closing the diagnostic gap during early seroconversion.

Engineers modify reovirus capsid proteins to overcome limited efficacy against rare cancers and taxane-resistant tumors.

Stabilized gp41 peptides expose the 2F5 epitope while occluding hydrophobic regions, resolving immune recognition barriers for HIV vaccine development.

Co-expressing bacteriophage capsid proteins with double stranded RNA in microbial cells enables high quantity accumulation of unencapsidated product.

Simian adenovirus vectors minimize pre-existing immunity interference to enhance vaccine efficacy.

Targeted VP3 residue modifications prevent ubiquitination, boosting transduction efficiency across hard-to-transduce cells.

Lentiviral vector delivers large S antigen to eliminate intracellular HBV DNA and resolve drug resistance.

Targeted antibodies neutralize hepatitis B and delta viruses by clearing surface antigens, resolving chronic treatment limitations.

Segmenting the viral genome into a minimal replicon and expression cassette boosts EB-VLP yield while removing extracellular vesicle contamination.

Re-ordered HPV16 E6 and E7 peptide fragments induce strong immune responses while minimizing oncogenic transformation risk.

Amino acid modifications in AAV capsids boost heparan sulfate binding, resolving limited intravitreal transduction efficiency.

A peptide panel detects HIV antibodies across multiple subtypes using conserved envelope regions.

Detect IgA antibodies against SEQ ID NO: 1 to resolve low sensitivity in early infection stages and eliminate cross-reactivity with seasonal coronaviruses.

Inserting a specific peptide sequence into the AAV capsid reduces liver transduction and toxicity while boosting muscle gene expression.

Nucleic acid cassettes with artificial introns express overlapping open reading frames in insect cells for recombinant adeno-associated virus production.

Myomesin-derived polypeptides mimic HIV-1 envelope glycoprotein epitopes to elicit broadly neutralizing antibodies.

Sequential chromatography matrices isolate virus-like particles from bacterial homogenates to achieve high purity.

Restructuring the MVA genome creates stable insertion sites for heterologous DNA sequences, preventing genetic instability and loss of foreign gene expression.

Reducing agents cleave HBsAg disulfide bonds to linearize the antigen, eliminating strong acid pretreatment and autoantibody interference.

Point mutations in hexon, fiber, and penton proteins prevent binding to coagulation factor 10 and CAR receptors, reducing off-target sequestration.

Extracted vaccinia polypeptides elicit cell-mediated immunity while reducing reactogenicity from whole-virus vaccines.

Optimized CDR amino acid parameters resolve cross-reactivity contradictions, ensuring accurate detection of target viral antigens.

A hydrophobic interaction chromatography method combines flow-through and bind-elute techniques to purify proteins.

Targeting novel porcine rotavirus B genotype G12, the vaccine overcomes insufficient maternal antibody protection against neonatal diarrhea outbreaks.

Recombinant AAV vectors with specific amino acid substitutions enhance T-cell transduction efficiency while maintaining capsid structural stability.

Modified AAVrh.10 particles bypass pre-existing neutralizing antibodies to expand patient eligibility for liver-targeted gene therapy.

Targeted amino acid substitutions in viral proteins increase oncolytic activity while preserving tumor specificity for cancer therapy.

AAV Clade F vectors enable precise genome editing without exogenous nucleases, resolving the trade-off between transduction efficiency and safety risks.

Recombinant bacteriophage fusion proteins bind bacterial surfaces to enable rapid enrichment and specific detection without lengthy cultivation.

Deleting ORFV112 and ORFV111 genes removes viral immune evasion mechanisms, resolving the contradiction between oncolytic activity and host defense.